Johnson & Johnson Receives European Commission Approval for Tecvayli in Multiple Myeloma

Johnson & Johnson today announced that the European Commission has approved Tecvayli (teclistamab-cqyv) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies in the European Union. The approval was based on results from the MajesTEC-1 trial, which demonstrated an overall response rate of 63% with a median duration of response of 18.4 months. This approval makes Tecvayli available to multiple myeloma patients across all EU member states. J&J is committed to ensuring broad patient access to Tecvayli in Europe.